Levetiracetam Tablet, Film Coated
Product Images NDC 43547-222

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43547-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 02)

An equation for calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and a factor for female patients. The formula includes adjustments for weight in kilograms, age in years, and serum creatinine levels in mg/dL, with a multiplication factor of 0.85 for female patients.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 03)

An instructional diagram showing the formula to calculate creatinine clearance normalized to body surface area, expressed as CLcr (mL/min/1.73m²), by dividing creatinine clearance by the subject's body surface area and multiplying by 1.73.*

FDA Label Image

Levetiracetam Structural Formula (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 04)

Chemical structure of levetiracetam, depicting the molecular diagram with labeled atoms and bonds as visible in the image.*

FDA Label Image

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 05)

A bar chart titled 'Responder Rate (≥50% Reduction From Baseline) In Study 1' comparing the percentage of patients achieving response between placebo and two dosages of levetiracetam (1000 mg/day and 3000 mg/day). The placebo group (N=95) shows 7.4% response, levetiracetam 1000 mg/day (N=97) shows 37.1%, and levetiracetam 3000 mg/day (N=101) shows 39.6%. Statistically significant differences versus placebo are noted.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 06)

Bar chart showing responder rates (greater than 50% reduction from baseline) in Study 2, Period A, comparing placebo with Levetiracetam 1000 mg/day and 2000 mg/day. The y-axis represents the percentage of patients, with placebo at 6.3%, Levetiracetam 1000 mg/day at 20.8%, and Levetiracetam 2000 mg/day at 35.2%. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 07)

Bar chart titled 'Responder Rate (≥50% Reduction From Baseline) In Study 3' comparing placebo with Levetiracetam 3000 mg/day. The y-axis shows percent of patients, with placebo at 14.4% response (N=104) and Levetiracetam at 39.4% response (N=180). An asterisk denotes statistical significance versus placebo.*

FDA Label Image

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 08)

A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to placebo and levetiracetam. The graph shows a 19.6% responder rate for placebo (N=97) and a 44.6% responder rate for levetiracetam (N=101), with a note indicating statistical significance for levetiracetam versus placebo.*

FDA Label Image

Figure 5 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 09)

A bar chart comparing the percentage of patients between a placebo group (19.6%) and a Levetiracetam group (43.1%). The chart notes the number of patients in each group (Placebo N=51, Levetiracetam N=58) and indicates a statistically significant difference versus placebo.*

FDA Label Image

Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 10)

A bar chart showing responder rates (%) with more than 50% reduction in PGTC seizure frequency per week in Study 7. The chart compares placebo (45.2%, N=84) versus levetiracetam (72.2%, N=79), with a note indicating statistical significance versus placebo.*

FDA Label Image

250 mg 120 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 11)

Levetiracetam Tablets, USP 250 mg film-coated oral tablets. The label indicates the product is for Rx only and contains 120 tablets. It includes directions to dispense with medication guides and storage instructions. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. and distributed by Solco Healthcare US, LLC.*

FDA Label Image

500 mg 120 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 12)

Levetiracetam Tablets USP 500 mg film-coated oral tablets label, on a blue and white background. The label indicates a count of 120 tablets. It includes storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd., and distributor Solco Healthcare US, LLC. The label features a pink, oval-shaped tablet image and a barcode on the left side.*

FDA Label Image

750 mg 120 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 13)

Levetiracetam 750 mg film-coated tablets label showing the brand and generic name, strength, and dosage form. The label indicates 120 tablets per container, prescription only status, and storage instructions. It includes manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd. and distributor Solco Healthcare US, LLC information, with barcode and regulatory details.*

FDA Label Image

1000 mg 60 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 14)

Levetiracetam Tablets, USP 1000 mg oral film-coated tablets in a blister pack. The label indicates the product contains 60 tablets and is distributed by Solco Healthcare US, LLC. The label notes manufacturing by Zhejiang Huahai Pharmaceutical Co., Ltd. Storage instructions specify 20-25°C with permitted excursions. The packaging includes a barcode and directs users to dispense accompanying medication guide.*

FDA Label Image

Trademark (Image 01)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.